Background: The incidence of esophageal adenocarcinoma in Europe and the United States rapidly increased from the latter half of the 1970s and exceeded that of esophageal squamous cell carcinoma in the latter half of the 1990s, currently accounting for approximately 60% of all esophageal carcinomas. Recently, its incidence has also increased in Japan, raising concerns that it will follow a course similar to that in Europe and the United States. Summary: The incidence of esophageal adenocarcinoma in Japan was about 2% until the 1990s, but in recent years, it has risen to 6.5–7.1%. Causes include the increase in the incidence of obesity due to changes in eating habits with resultant increases in the incidence of hiatal hernia and reflux esophagitis, a decrease in the rate of Helicobacter pylori infection, and the increased interest of physicians in the gastroesophageal junction. The number of gastroesophageal reflux disease patients in Japan rapidly increased from the 1990s, which accordingly increased the number of Barrett’s esophageal adenocarcinoma patients from the latter half of the 1990s. Tabulation and analysis of 1,794 reported cases of Barrett’s esophageal adenocarcinoma in Japan showed that superficial cancers accounted for 77.6%, and that the concomitant rates of hiatal hernia and reflux esophagitis were high at 87 and 70% respectively. Key Message: The future trend in the incidence of Barrett’s esophageal adenocarcinoma in Japan will depend on the increase in the incidence of reflux esophagitis, which is essential for the development of Barrett’s esophagus and Barrett’s esophageal carcinoma. The obesity rate is lower in Japan than that in Europe and the United States, and the incidence and severity of reflux esophagitis are low. We expect that the incidence of Barrett’s esophageal adenocarcinoma in Japan will not rise as high as in Europe and the United States, and will remain below 10%.

Journal Section:
JGA Topic Review
Keywords:
Barrett’s esophagus, Esophageal adenocarcinoma, Gastroesophageal reflux disease
1.
Udagawa H, Ozawa S, Tachimori Y, et al: Comprehensive Registry of Esophageal Cancer in Japan (1988–1994), ed 1. Tokyo, The Japanese Society for Esophageal Diseases, 2000, pp 25–25.
2.
Tachimori Y, Ozawa S, Numasaki H, et al: Comprehensive Registry of Esophageal Cancer in Japan, 2006. Esophagus 2014; 11: 21–47.
3.
Ueda Y, Osada H, Osugi H, et al: Thoracic and cardiovascular surgery in Japan during 2005. Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2007; 55: 377–399.
4.
Masuda M, Kuwano H, et al: Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Thoracic and cardiovascular surgery in Japan during 2012. Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 2014; 62: 734–764.
5.
Shimosegawa T: The Japanese Society of Gastroenterology (ed): Evidence-Based Clinical Practice Guidelines for GERD, ed 2, 2015.
6.
Fujiwara Y: Recent epidemiology of GERD in the Japanese population. Nihon Shokakibyo Gakkai Zasshi 2017; 114: 1781–1789.
7.
Fujiwara Y, Arakawa T: Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009; 44: 518–534.
8.
Kinoshita Y, Adachi K, Hongo M, et al: Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. J Gastroenterol 2011; 46: 1092–1103.
9.
Kinoshita Y, Ishihara S, Ishimura N: Future perspective of research and clinical practice in gastroesophageal reflux disease. Nihon Shokakibyo Gakkai Zasshi 2017; 114: 1765–1773.
10.
Miwa H, Oshima T, Tomita T: Gastro-esophageal reflux disease: the recent trend in Japan. Clin J Gastroenterol 2008; 1: 133–138.
11.
el-Serag HB, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327–333.
12.
Sugimoto M, Uotani T, Ichikawa H, et al: Gastroesophageal reflux disease in time covering eradication for all patients infected with helicobacter pylori in Japan. Digestion 2016; 93: 24–31.
13.
Nakamura T, Tohyama H, Nagamachi Y: “Barrett’s esophagus” adenocarcinoma: a case report. Jpn J Surg 1980; 10: 137–141.
© 2018 Japanese Gastroenterological Association Published by S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.